28 Abstract 29 Purpose: To identify key dosimetric parameters that have close associations with tumor treatment 30 response and body weight change in SFRT treatments with a large range of spatial-fractionation 31 scale at dose rates of several Gy/min. 32 Methods: Six study arms using uniform tumor radiation, half-tumor radiation, 2mm beam array 33 radiation, 0.3mm minibeam radiation, and an untreated arm were used. All treatments were 34 delivered on a 320kV x-ray irradiator. Forty-two female Fischer 344 rats with fibrosarcoma tumor 35 allografts were used. Dosimetric parameters studied are peak dose and width, valley dose and 36 width, peak-to-valley-dose-ratio, volumetric average dose, percentage volume directly irradiated, 37 and tumor-and normal-tissue EUD. Animal survival, tumor volume change, and body weight 38 change (indicative of treatment toxicity) are tested for association with the dosimetric parameters 39 using linear regression and Cox Proportional Hazards models.
145 e : T/N in the table denotes Tumor EUD and normal tissue EUD. Tumor EUD is computed using 146 a= -10 and a tumor size of 1cm in diameter. Normal tissue EUD is computed using a=5 and a 147 volume of 2cm in diameter. Note that tumor EUD is lower than valley surface dose is because the 148 valley dose is measured at the surface while EUDs are computed using volumetric dose.
149
Custom-made radiation blocks and collimators made of Cerrobend or tungsten were used 150 to define the 2cmx2cm field for 20GyUniformRT arm treatment, the 2cmx1cm for 20GyHalfSFRT 
184
In preclinical studies the pre-treatment tumor volume is known to be strongly correlated 185 with treatment tumor control (23). We minimize this unwanted effect by controlling the pre-186 treatment tumor volume in a randomized, matched group study design. We binned animals 187 according to their pre-treatment tumor volume and then randomly assigned these matched bins 188 of animals such that at least one animal from each bin is assigned to each treatment group. This 189 technique resulted in an average initial tumor volume across groups of 566 +/-47 mm 3 on RT 190 treatment day. Biological variability was minimized by ordering animals from the same vendor 191 and of the same age (6 weeks old), implanting tumor on the same day and from the same donor 192 animal, treating with radiation on the same day, and housing animals in the same Vivarium 193 location with identical husbandry conditions. All animals (mixed caged) were provided identical 194 standard laboratory rodent diets of (23%> crude protein) and water ad libitum throughout the 195 study. In addition, all animal diets were supplemented with high-calorie, nutritionally fortified 224 treatment verification films with a cutout in the tumor region. The films were reviewed for all treated 225 animals for treatment targeting verification. 226 227 Fig 3. Phantom dosimetry measurement. 228 EBT-3 films were calibrated by ion chamber under large field conditions. All beam profiles and 229 corresponding percentage depth dose were measured using two films as shown: one is on the 230 surface perpendicular to radiation beam (A) and one sandwiched between two small phantom 231 blocks parallel to radiation beam (B). The circles indicate the film areas used for volume-average 232 dose calculation estimates. The following assumption was made for volume-averaged tumor 233 dose and EUD calculations: dose value does not vary +/-1cm along the direction parallel to the 234 same valleys/peaks. 235 236 
Tumor volume imaging and body weight monitoring 259
Three-dimensional B-mode ultrasound imaging of the tumors was performed using a Vevo 260 770 preclinical ultrasound scanner (Vevo 770, VisualSonics, Toronto, ON, Canada) and the 261 resulting images used to calculate tumor volume, as described in a previous publication (23).
262 Imaging was performed on the day before treatment as well as every third day post-treatment for 263 approximately 30 days, or when maximal tumor burden was met, at which point the animals were 264 humanely sacrificed per IACUC-approved animal protocol. Table S1 ). Peak dose (R 2 =0.04472, F-stat=0.6874 (not sig.)) and AVG 354 Dose (R 2 = 0.2745, F-stat=1.514 (not sig.)) showed little association with survival. 
439
The potential impact of spatial fractionation pattern (lines vs. dots, for instance) on treatment 440 response is beyond the scope of this work. However, it is a very important question that deserves 441 methodical investigations as some spatial fractionation patterns are easier to achieve than others 442 in practical application. Our data shows that valley/minimum dose has the closest association 443 with treatment response for tumor and body weight. However, different spatial fractionation 444 patterns with the same valley dose may not lead to the same treatment response when a different 445 endpoint is used. In our study the 20Gy2mmSFRT arm and the 20GySFRT arm have similar 446 valley doses but dissimilar survival fraction on Day 17. To investigate the impact of radiation 447 spatial fractionation pattern alone on given treatment responses, carefully designed new studies 448 are needed.
449
The exciting noncytotoxic effects of SFRT, such as induction therapy to sensitize tumor to 450 increase therapeutic ratio of the following therapy including anti-tumor immunotherapy, remain 451 largely underexplored (32); however, they are also beyond of the scope of this work. Our own 452 and others' work have demonstrated that SFRT radiation impacts tumor microenvironment and 453 modulates immune system very differently than uniform radiation therapy (33-35). We intend to 454 conduct similar studies to identify associations between dosimetric parameters and these indirect 455 effects of SFRT in the future. 470 S1 Table) . This observed association between tumor treatment response with tumor 471 valley/minimum dose and tumor EUD dose in this preclinical study is consistent with their known 472 association in tumor treatment response seen in clinical conventional uniform dose radiation 473 therapy.
474
Our data suggests that valley/minimum dose or Tumor EUD are more appropriate than 475 peak dose for SFRT treatment prescription. When tumor control is the endpoint, we suggest that 476 equal valley or minimum dose be used for comparative study between a uniform radiation and 477 SFRT therapy or among different SFRT treatments.
478 479 PVDR 505 sig.)). In a synchrotron microbeam brain study using multiple beams Serduc et al. kept valley 506 dose constant while varying peak width and peak dose. They concluded that the latter two 507 parameters have strong influence therapeutic ratio (39).
508

Volume-averaged dose and peak dose 509
This study is designed to scrutinize the association of volume-averaged dose with tumor 510 treatment response (Fig 1) . The four study arms sharing very similar volume-averaged doses (20 511 or 18 Gy) exhibited very different tumor treatment responses (Fig 6 and 7) showing the survival 512 rate at day 17 varied from 100% to 33%. Therefore, the association between volume-average 513 dose and tumor treatment response is weak.
514
We found that peak dose has little to no association with tumor treatment response 515 (R 2 =0.04472, F-stat=0.6874 (not sig.)) (Fig 7, S1 Table, Table 2 ). This finding is significant 516 because peak dose has been used for treatment prescription in practically all SFRT treatments 517 (8) (9). Although the linear regression analysis on day 17 showed a weak association between 518 peak dose and survival that was not statistically significant, the CoxPH analysis using the entire 519 survival data set did show a modest association with survival.
SFRT dosimetric association with normal tissue toxicity 521
We did not study treatment induced normal tissue toxicity directly in this study. We used 522 body weight change post radiation (targeted to the flank, lower abdominal region of the animal) 523 as an indicator, not an evidence of normal tissue toxicity. We did not see a strong association 524 between animal body weight change and any of the eight dosimetric parameters studied, except 525 a modest association with valley/minimum dose.
526
Valley dose 527
The strongest association we observed is a weak one between body weight change and 528 valley/min dose (R 2 =0.3814, F-stat=13.56**) ( 
2mm wide beam array SFRT 553
Our data indicates that the 20Gy2mmSFRT arm is not only the most relevant to clinical 554 application because of its millimeter scale, but it also has the potential for superior therapeutic 555 ratio. The 20Gy2mmSFRT arm showed similar survival with the 50GySFRT arm but has 556 significantly lower valley dose (6.2 Gy vs. 17 Gy). At the same time, it showed the least, if any, 557 body weight change compared to the untreated arm while the 50GySFRT arm with 0.31mm beam 558 width exhibited significant body weight growth deficit (Table 1 and Fig 6) . The 20GyUniform arm 559 has the best tumor treatment response and the worst body weight change. Our data indicated the 560 2mm wide beam array is a kV photon SFRT pattern that has the potential for high therapeutic 561 ratio SFRT and deserves further investigation.
562 Cross-correlation in the SFRT dosimetry parameters 563
The dosimetric parameters studied in this work are not all independent variables and their 564 cross-correlations are shown in the table of Pearson Correlation coefficients (Table 4 .) The larger 565 the magnitude of the coefficient, the more co-linear and correlated the pair of dosimetric 566 parameters. In this study, peak width and valley width are perfectly co-linear (correlation of 1.0) 567 by study design. Valley/min dose, a parameter used in tumor EUD calculation, is also highly 568 correlated with tumor EUD (correlation of 0.99). These strong correlations explain the similar 569 statistical associations of these parameters with treatment responses. These correlations also 570 limited the study's ability to better exam the association between a given treatment response with 571 each of the dosimetric parameters. In this conventional dose rate small animal SFRT study we used a large range of radiation 578 spatial fractionation scales to study the association of dosimetric parameters with treatment 579 response. We concluded that valley/minimum dose, tumor EUD, and percentage tumor irradiated
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